Tollovir still the only 3CL protease inhibitor sho
Post# of 1418
![Avatar](/images/ProfileImages/1996739806_13310_Entertained 3.jpg)
New Data for Shionogi's COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance - April 23, 2022 11:15 AM
https://www.benzinga.com/pressreleases/22/04/...-clearance
Gerald Commissiong@G_Commish Apr 20
"Tollovir compassionate use going well, will update on numbers soon. Final analysis with p values soon also. We have our strategy now and will be pushing hard Europe/US/Israel. Top level people getting behind 3CL Pharma, just got monster hosp valuation , Long COVID valuation next"
That 3rd party, independent valuation is key to negotiations. Let's say it's $100M. That means to get $10M of funding you aren't giving up much. But what if the valuation is North of $1B? It's entirely possible with key milestones. The other crap-o drugs are valued much higher.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)